Check out your Company Bowl for anonymous work chats.
Adaptive and Amgen collaborate to develop therapeutic antibodies against SARS-CoV-2
Help us understand how different people respond to the COVID-19 virus Be part of the ImmuneRACE. If you’ve been impacted by COVID-19, your immune system may hold key information that can help contain and manage the virus.
We’re partnering with Illumina to develop IVD test kits for our clonoSEQ Assay, to help physicians detect and monitor minimal residual disease (MRD) in blood cancer patients, and our immunoSEQ Dx Assay for pipeline indications. The agreement is a significant step in expanding access to our portfolio of next-generation sequencing-based #immunodiagnostics. Learn more: http://glassdoor.com/slink.htm?key=vM0kP For additional info, including test limitations: http://glassdoor.com/slink.htm?key=vM0kd http://glassdoor.com/slink.htm?key=vM0k9
Adaptive Biotechnologies Enters Partnership for Use Of clonoSEQ® as Preferred MRD Test for Drug Development Across Amgen’s Hematology Franchise http://glassdoor.com/slink.htm?key=vM0CG
Adaptive is growing!
http://glassdoor.com/slink.htm?key=vMcyn
Be sure to catch the latest episode of the @Fuel Talent #WhatFuelsYou podcast with CEO Chad Robins as he describes the path that led him to Adaptive, lessons he’s learned along the way, and the importance of building an organic, transparent company culture. Listen here: http://glassdoor.com/slink.htm?key=vQZTO
Excited to announce that our employees voted us one of @PSBJ Best Places to Work! http://glassdoor.com/slink.htm?key=vQMek
